Moderna’s Patent Estate

Moderna has pioneered the development of modified messenger RNA (mRNA) medicines since our founding. We are the undisputed leader in the space, having advanced 12 programs using modified mRNA technologies into development, and we remain the only party to have advanced a modified mRNA medicine into clinical study. As of January 2017, we have announced five clinical programs for internal and partnered mRNA therapeutics and vaccines.

Along the way, we have amassed a broad and deep patent estate that we believe is unrivaled in the mRNA space. This includes foundational patents in modified mRNA technologies and delivery technologies that are essential for mRNA therapeutics and vaccines, including their application in specific unmet needs in infectious diseases, cancer (immuno-oncology), and rare and cardiometabolic diseases, among others.

To date, Moderna has been granted over 50 patents in the United States, Europe, Japan and other jurisdictions, protecting fundamental inventions in the mRNA therapeutics space, with several hundred additional pending patent applications covering key advances in the field. We have augmented our internal patent estate with over ten in-licensed patent estates, including licenses to pioneering discoveries by Derrick Rossi, Ph.D. and colleagues at Harvard University, and Katalin Karikó, Ph.D. and colleagues at the University of Pennsylvania.

Looking forward, we believe mRNA is at the beginning of a 20-year innovation cycle. We continue to invest aggressively in science and technology and build an ever- broader patent portfolio to ensure Moderna is in the strongest possible position to deliver on the promise of mRNA to bring a new class of transformative medicines to patients in the decades to come.